{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Psoriasis+Chronic&page=3", "query": { "condition": "Psoriasis Chronic", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 146, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Psoriasis+Chronic&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Psoriasis+Chronic&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T13:06:18.711Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04870827", "title": "Effect of Chronic Inflammation on Myocardial Perfusion and Function", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "13N Amonia", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2021-06-07", "completion_date": "2022-05-18", "has_results": false, "last_update_posted_date": "2023-04-06", "last_synced_at": "2026-10-21T13:06:18.711Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04870827" }, { "nct_id": "NCT00419666", "title": "A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Plaque Psoriasis" ], "interventions": [ { "name": "Calcitriol 3mcg/g", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Galderma R&D", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "12 Years to 17 Years" }, "enrollment_count": 25, "start_date": "2006-08-01", "completion_date": "2009-09-24", "has_results": true, "last_update_posted_date": "2021-02-18", "last_synced_at": "2026-10-21T13:06:18.711Z", "location_count": 5, "location_summary": "Little Rock, Arkansas • San Diego, California • Eagan, Minnesota + 2 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "San Diego", "state": "California" }, { "city": "Eagan", "state": "Minnesota" }, { "city": "Houston", "state": "Texas" }, { "city": "Webster", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00419666" }, { "nct_id": "NCT00941031", "title": "AIN457 Regimen Finding Study in Patients With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Plaque-type Psoriasis" ], "interventions": [ { "name": "AIN457", "type": "DRUG" }, { "name": "AIN457A", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 404, "start_date": "2009-07", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2015-08-20", "last_synced_at": "2026-10-21T13:06:18.711Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Pasadena, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Pasadena", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00941031" }, { "nct_id": "NCT02326272", "title": "A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Psoriasis", "Plaque Psoriasis" ], "interventions": [ { "name": "Certolizumab Pegol", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "UCB Biopharma S.P.R.L.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 227, "start_date": "2014-12-15", "completion_date": "2018-09-12", "has_results": true, "last_update_posted_date": "2019-10-03", "last_synced_at": "2026-10-21T13:06:18.711Z", "location_count": 14, "location_summary": "Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 11 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Ormond Beach", "state": "Florida" }, { "city": "Portsmouth", "state": "New Hampshire" } ], "official_url": "https://clinicaltrials.gov/study/NCT02326272" }, { "nct_id": "NCT04211363", "title": "Trial of PDE4 Inhibition With Roflumilast for the Management of Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Plaque Psoriasis" ], "interventions": [ { "name": "Roflumilast 0.3% cream", "type": "DRUG" }, { "name": "Vehicle Cream", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcutis Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 439, "start_date": "2019-12-20", "completion_date": "2020-11-16", "has_results": true, "last_update_posted_date": "2022-12-07", "last_synced_at": "2026-10-21T13:06:18.711Z", "location_count": 31, "location_summary": "Encinitas, California • Fremont, California • Irvine, California + 26 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Fremont", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04211363" }, { "nct_id": "NCT03840928", "title": "PatientSpot Formerly Known as ArthritisPower", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Rheumatoid Arthritis", "Ankylosing Spondylitis", "Fibromyalgia", "Gout", "Crohn Disease", "Juvenile Idiopathic Arthritis", "Lupus Erythematosus", "Myositis", "Osteoarthritis", "Osteoporosis", "Psoriasis", "Psoriatic Arthritis", "Scleroderma", "Dermatomyositis", "Inflammatory Bowel Diseases", "Polymyositis", "Axial Spondyloarthritis", "Diffuse Idiopathic Skeletal Hyperostosis", "Polymyalgia Rheumatica", "Giant Cell Arteritis", "Temporal Arteritis", "Wegener", "Relapsing Polychondritis", "Undifferentiated Connective Tissue Disease", "Spinal Cord Injuries", "Alzheimer Disease", "Amyotrophic Lateral Sclerosis", "Ataxia", "Bell Palsy", "Brain Tumor", "Cerebral Aneurysm", "Epilepsy", "Guillain-Barre Syndrome", "Headache", "Head Injury", "Hydrocephalus", "Lumbar Disc Disease", "Meningitis", "Multiple Sclerosis", "Muscular Dystrophy", "Neurocutaneous Syndromes", "Parkinson Disease", "Stroke", "Cluster Headache", "Tension-Type Headache", "Chronic Obstructive Pulmonary Disease", "Asthma", "Lung Cancer", "Cystic Fibrosis", "Sleep Apnea", "Eczema", "Alopecia", "Chronic Inflammation", "Unstable Angina", "Heart Attack", "Heart Failure", "Arrythmia", "Valve Heart Disease", "High Blood Pressure", "Congenital Heart Disease", "Peripheral Arterial Disease", "Diabetes", "Chronic Liver Disease", "Obesity" ], "interventions": [], "intervention_types": [], "sponsor": "Global Healthy Living Foundation", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 40000, "start_date": "2015-04-01", "completion_date": "2025-03-01", "has_results": false, "last_update_posted_date": "2023-12-13", "last_synced_at": "2026-10-21T13:06:18.711Z", "location_count": 1, "location_summary": "Upper Nyack, New York", "locations": [ { "city": "Upper Nyack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03840928" }, { "nct_id": "NCT02471144", "title": "Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Severe Plaque-type Psoriasis" ], "interventions": [ { "name": "Experimental : Secukinumab low dose", "type": "BIOLOGICAL" }, { "name": "Experimental: Secukinumab high dose", "type": "BIOLOGICAL" }, { "name": "Placebo Comparator: Secukinumab Placebo", "type": "BIOLOGICAL" }, { "name": "Active Comparator: Etanercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 162, "start_date": "2015-09-29", "completion_date": "2023-03-30", "has_results": true, "last_update_posted_date": "2023-10-11", "last_synced_at": "2026-10-21T13:06:18.711Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02471144" }, { "nct_id": "NCT00168753", "title": "Community Based Trial for AMEVIVE®", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Moderate to Severe Chronic Plaque Psoriasis" ], "interventions": [ { "name": "Alefacept", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 114, "start_date": "2004-07", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2014-09-08", "last_synced_at": "2026-10-21T13:06:18.711Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Anchorage, Alaska + 33 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairhope", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Bakersfield", "state": "California" }, { "city": "Riverside", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00168753" }, { "nct_id": "NCT03384745", "title": "A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "M1095 (Sonelokimab)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Secukinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bond Avillion 2 Development LP", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 313, "start_date": "2018-07-31", "completion_date": "2020-03-26", "has_results": true, "last_update_posted_date": "2021-08-03", "last_synced_at": "2026-10-21T13:06:18.711Z", "location_count": 11, "location_summary": "Birmingham, Alabama • San Diego, California • DeLand, Florida + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Sandy Springs", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03384745" }, { "nct_id": "NCT02949388", "title": "Efficacy and Safety of Prurisol Administered Orally for Active Moderate to Severe Chronic Plaque Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Stable Plaque Psoriasis" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "400 mg (200 mg BID)", "type": "DRUG" }, { "name": "300 mg (150 mg BID)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Innovation Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 199, "start_date": "2016-11", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2018-02-13", "last_synced_at": "2026-10-21T13:06:18.711Z", "location_count": 34, "location_summary": "Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 27 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Rogers", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02949388" } ] }